Ribo Biopharma Achieves First Key Milestone in siRNA Collaboration with Boehringer Ingelheim for MASH Therapy

Suzhou Ribo Life Science Co., Ltd. and its international R&D center Ribocure Pharmaceuticals AB (collectively referred to as “Ribo Life Science”) are pleased to announce that they have achieved the first key milestone agreed upon in the collaboration agreement with Germany’s Boehringer Ingelheim.Click here to view the original announcement from Boehringer Ingelheim)。

On January 3, 2024, Ribo Life Science and Boehringer Ingelheim announced a significant collaboration agreement to jointly develop innovative small nucleic acid therapies for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH).Click the link to view details)The breakthrough progress achieved by both parties in less than a year since the official launch of the project not only demonstrates Boehringer Ingelheim's professional strength in the MASH treatment field but also proves the solidity of Ribo Life Science's small nucleic acid technology platform and the team's excellent and efficient international cooperation capabilities. It is expected that under the joint efforts of both parties, multiple subsequent milestones will be continuously achieved, providing new treatment options for MASH patients.

      About Boehringer Ingelheim

Boehringer Ingelheim is dedicated to researching breakthrough therapies aimed at transforming lives and safeguarding the health of generations to come. As a globally leading biopharmaceutical company driven by innovation, it delivers value through advancements in areas of high unmet medical need. Since its founding in 1885, Boehringer Ingelheim has remained an independent, family-owned business with a long-term perspective. With over 53,000 employees across human pharmaceuticals and animal health sectors, the company serves more than 130 regions worldwide. For more information, please visit: www.boehringer-ingelheim.com.

      About Ribo Life Science and Ribo International Research and Development Center

     Ribo Life Science is an innovative R&D company dedicated to developing RNA interference (RNAi) drugs and is a leading pioneer and major player in China’s small nucleic acid technology and small nucleic acid pharmaceutical industry. Ribo Life Science aligns itself with the cutting-edge innovations in international small nucleic acid technology, focusing on the iterative R&D of small nucleic acid chemical modifications and drug delivery technologies. The company has established an independent, fully integrated R&D platform for small nucleic acid drugs that supports all stages of research from early development to industrialization. The company has built a rich product pipeline targeting cardiovascular metabolic diseases, liver diseases, kidney diseases, and rare diseases. By adhering to a strategy of differentiated target selection and product positioning, Ribo Life Science boasts an international team of innovators who conduct R&D and commercialization globally, striving to bring new therapeutic options to patients as soon as possible. For more information, please seewww.ribolia.com。
     Ribo Life Science International R&D Center is located in Gothenburg, Sweden. It serves as the company’s global base for clinical development and business growth, with a professional team that has an international perspective and strong global clinical development capabilities. The center has established clinical trial sites and laboratories, leading and driving the global clinical trials and business development of innovative small nucleic acid drugs. For more information, please refer towww.ribocure.com。